[Current status of the treatment of recurrent acute myeloblastic leukaemia in adults (author's transl)].
D000609:Aminoacridines / Q000008:administration & dosage; D000677:Amsacrine; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001374:Azacitidine / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D003630:Daunorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives; D004317:Doxorubicin / Q000008:administration & dosage; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008935:Mitoguazone / Q000008:administration & dosage; D012008:Recurrence
D000609:Aminoacridines; D000970:Antineoplastic Agents; D000677:Amsacrine; D005047:Etoposide; D004317:Doxorubicin; D001374:Azacitidine; D008935:Mitoguazone; C002205:zorubicin; D003630:Daunorubicin
La situación actual del tratamiento de la leucemia aguda mieloblástica (LAM) recurrente en el adulto.